Skip to content

Study · Animal study (in vivo) · rat · 2005

7 results

Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats.

Boban Blagaic A, Blagaic V, Mirt M, Jelovac N, Dodig G, Rucman R, Petek M, Turkovic B, Anic T, Dubovecak M, Staresinic M, Seiwerth S, Sikiric P

European journal of pharmacology1 Apr 2005Cited by 29 (Europe PMC)

PMID15840402 (opens in a new tab)DOI10.1016/j.ejphar.2005.02.033 (opens in a new tab)PepBankPUB-15840402
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given pargyline and L-tryptophan, BPC‑157 considerably inhibited severe serotonin syndrome, including at lower dose regimens.

    In plain wordsIn rats with severe serotonin syndrome, BPC‑157 strongly reduced the syndrome, even at lower doses.

    Peptide
    BPC-157
    Outcome
    DecreaseSevere serotonin syndrome in pargyline + L-tryptophan rats
    Study

    ratn: not reported in source

    Pargyline plus L-tryptophan serotonin syndrome
    Outcome group
    Serotonin syndrome · Nervous system and cognition
    Studied dose
    10 microg, 10 ng or 10 pg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    severe serotonin syndrome in pargyline + L-tryptophan rats is considerably inhibited even by lower pentadecapeptide BPC 157 doses regimens
    1 context sentence
    Summary · context
    we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor; 100 mg/kg i.p.; BPC 157 as a co-treatment)
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pargyline plus L-tryptophan serotonin syndrome, BPC‑157 inhibited disturbances such as hyperthermia.

    In plain wordsIn rats with severe serotonin syndrome, BPC‑157 reduced the rise in body temperature.

    Peptide
    BPC-157
    Outcome
    DecreaseHyperthermia in severe serotonin syndrome
    Study

    ratn: not reported in source

    Pargyline plus L-tryptophan serotonin syndrome
    Outcome group
    Serotonin syndrome · Nervous system and cognition
    Studied dose
    10 microg, 10 ng or 10 pg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    particularly disturbances such as hyperthermia and wet dog shake thought to be related to stimulation of 5-HT2A receptors)
    1 context sentence
    Summary · context
    we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor; 100 mg/kg i.p.; BPC 157 as a co-treatment)
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pargyline plus L-tryptophan serotonin syndrome, BPC‑157 inhibited disturbances such as wet dog shake.

    In plain wordsIn rats with severe serotonin syndrome, BPC‑157 reduced wet dog shake behaviour.

    Peptide
    BPC-157
    Outcome
    DecreaseWet dog shake in severe serotonin syndrome
    Study

    ratn: not reported in source

    Pargyline plus L-tryptophan serotonin syndrome
    Outcome group
    Serotonin syndrome · Nervous system and cognition
    Studied dose
    10 microg, 10 ng or 10 pg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    particularly disturbances such as hyperthermia and wet dog shake thought to be related to stimulation of 5-HT2A receptors)
    1 context sentence
    Summary · context
    we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor; 100 mg/kg i.p.; BPC 157 as a co-treatment)
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given pargyline alone, the highest BPC‑157 dose counteracted mild hypothermia.

    In plain wordsIn rats given pargyline, the highest BPC‑157 dose countered mild low body temperature.

    Peptide
    BPC-157
    Outcome
    DecreaseMild hypothermia in pargyline rats
    Study

    ratn: not reported in source

    Pargyline alone
    Outcome group
    Serotonin syndrome · Nervous system and cognition
    Studied dose
    highest dose tested · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    the highest pentadecapeptide dose counteracts mild disturbances present in pargyline rats (mild hypothermia, feeble hind limbs abduction)
    1 context sentence
    Summary · context
    (ii, iii) using pargyline or L-tryptophan given separately, as a serotonin-substrate with (ii) pargyline (BPC 157 as a 15-min posttreatment)
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats given pargyline alone, the highest BPC‑157 dose counteracted feeble hind limbs abduction.

    In plain wordsIn rats given pargyline, the highest BPC‑157 dose countered mild hind limb spreading.

    Peptide
    BPC-157
    Outcome
    DecreaseFeeble hind limbs abduction in pargyline rats
    Study

    ratn: not reported in source

    Pargyline alone
    Outcome group
    Serotonin syndrome · Nervous system and cognition
    Studied dose
    highest dose tested · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    the highest pentadecapeptide dose counteracts mild disturbances present in pargyline rats (mild hypothermia, feeble hind limbs abduction)
    1 context sentence
    Summary · context
    (ii, iii) using pargyline or L-tryptophan given separately, as a serotonin-substrate with (ii) pargyline (BPC 157 as a 15-min posttreatment)
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats given L-tryptophan alone, BPC‑157 had no influence on the L-tryptophan challenge and did not induce serotonin syndrome.

    In plain wordsIn rats given L-tryptophan, BPC‑157 did not change the response and did not cause serotonin syndrome.

    Peptide
    BPC-157
    Outcome
    No significant changeSerotonin syndrome induction by L-tryptophan challenge
    Study

    ratn: not reported in source

    L-tryptophan challenge alone
    Outcome group
    Serotonin syndrome · Nervous system and cognition
    Studied dose
    10 microg, 10 ng or 10 pg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    nor an inductor for serotonin syndrome (no influence on L-tryptophan challenge)
    1 context sentence
    Summary · context
    (iii) L-tryptophan (BPC 157 as a 15 min-pretreatment)
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In rats, BPC‑157 given alone had no behavioral or temperature effect.

    In plain wordsIn rats, BPC‑157 given alone did not change behaviour or body temperature.

    Peptide
    BPC-157
    Outcome
    No significant changeBehavior and temperature with BPC 157 alone
    Study

    ratn: not reported in source

    BPC 157 alone
    Outcome group
    Serotonin syndrome · Nervous system and cognition
    Studied dose
    10 microg, 10 ng or 10 pg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    alone, no behavioral or temperature effect
    1 context sentence
    Summary · context
    we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor; 100 mg/kg i.p.; BPC 157 as a co-treatment)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.